These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 31796516)

  • 1. Significance of
    Chakraborty G; Armenia J; Mazzu YZ; Nandakumar S; Stopsack KH; Atiq MO; Komura K; Jehane L; Hirani R; Chadalavada K; Yoshikawa Y; Khan NA; Chen Y; Abida W; Mucci LA; Lee GM; Nanjangud GJ; Kantoff PW
    Clin Cancer Res; 2020 Apr; 26(8):2047-2064. PubMed ID: 31796516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in
    Chakraborty G; Patail NK; Hirani R; Nandakumar S; Mazzu YZ; Yoshikawa Y; Atiq M; Jehane LE; Stopsack KH; Lee GM; Abida W; Morris MJ; Mucci LA; Danila D; Kantoff PW
    Clin Cancer Res; 2021 Mar; 27(6):1792-1806. PubMed ID: 33334906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
    Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
    EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
    Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.
    Iwasawa T; Kosaka T; Morita S; Mikami S; Nakamura K; Hongo H; Nishihara H; Oya M
    BMC Med Genomics; 2022 Jun; 15(1):138. PubMed ID: 35725469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
    J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer.
    Barnett ES; Schultz N; Stopsack KH; Lam ET; Arfe A; Lee J; Zhao JL; Schonhoft JD; Carbone EA; Keegan NM; Wibmer A; Wang Y; Solit DB; Abida W; Wenstrup R; Scher HI
    Eur Urol; 2023 Feb; 83(2):112-120. PubMed ID: 36123219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double Trouble: Concomitant
    Mandigo AC; Knudsen KE
    Clin Cancer Res; 2020 Apr; 26(8):1784-1786. PubMed ID: 32019859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomics of lethal prostate cancer at diagnosis and castration resistance.
    Mateo J; Seed G; Bertan C; Rescigno P; Dolling D; Figueiredo I; Miranda S; Nava Rodrigues D; Gurel B; Clarke M; Atkin M; Chandler R; Messina C; Sumanasuriya S; Bianchini D; Barrero M; Petermolo A; Zafeiriou Z; Fontes M; Perez-Lopez R; Tunariu N; Fulton B; Jones R; McGovern U; Ralph C; Varughese M; Parikh O; Jain S; Elliott T; Sandhu S; Porta N; Hall E; Yuan W; Carreira S; de Bono JS
    J Clin Invest; 2020 Apr; 130(4):1743-1751. PubMed ID: 31874108
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Miao C; Tsujino T; Takai T; Gui F; Tsutsumi T; Sztupinszki Z; Wang Z; Azuma H; Szallasi Z; Mouw KW; Zou L; Kibel AS; Jia L
    Sci Adv; 2022 Feb; 8(7):eabl9794. PubMed ID: 35179959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
    Cheng HH; Pritchard CC; Boyd T; Nelson PS; Montgomery B
    Eur Urol; 2016 Jun; 69(6):992-5. PubMed ID: 26724258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.
    Nava Rodrigues D; Casiraghi N; Romanel A; Crespo M; Miranda S; Rescigno P; Figueiredo I; Riisnaes R; Carreira S; Sumanasuriya S; Gasperini P; Sharp A; Mateo J; Makay A; McNair C; Schiewer M; Knudsen K; Boysen G; Demichelis F; de Bono JS
    Clin Cancer Res; 2019 Jan; 25(2):687-697. PubMed ID: 30257982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
    Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
    Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
    Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
    Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
    Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
    Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.